Article
Gastroenterology & Hepatology
Shigeo Shimose, Rie Sugimoto, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Yuki Tanaka, Fujimasa Tada, Hideko Ohama, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Yu Noda, Naoki Kamachi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Summary: This study evaluated the therapeutic effects and safety of ramucirumab following atezolizumab plus bevacizumab treatment. The results showed increased therapeutic effect in patients with atezolizumab plus bevacizumab failure, and patients with splenomegaly and low BMI should be monitored for ascites during ramucirumab treatment.
HEPATOLOGY RESEARCH
(2023)
Article
Oncology
Timothy J. Brown, Ronac Mamtani, Phyllis A. Gimotty, Thomas B. Karasic, Yu-Xiao Yang
Summary: The impact of etiology on outcomes of HCC patients treated with atezolizumab and bevacizumab was investigated, and no significant association between etiology and overall survival or time to treatment discontinuation was found.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, Hong Jae Chon
Summary: In the first-line treatment of unresectable HCC, ATE/BEV and LENV had comparable clinical efficacy and safety, with no significant differences observed.
Article
Oncology
Miyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Yasuharu Kikuchi, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Takashi Taida, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Masami Shinozaki, Jun Kato, Naoya Kato
Summary: This study investigated the long-term efficacy and adverse events of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma. It found that the median progression-free survival (PFS) for the first-line treatment group was 8.0 months, while the median PFS for the second- or later-line treatment group was 4.1 months, significantly worse than the first-line treatment group. Interrupted bevacizumab treatment, mainly due to proteinuria, was more common in patients with hypertension and/or diabetes mellitus. The landmark analysis suggested that the interruption of bevacizumab may be associated with impaired efficacy of atezolizumab plus bevacizumab over the long term.
Article
Gastroenterology & Hepatology
Fabian Jost-Brinkmann, Muenevver Demir, Alexander Wree, Tom Luedde, Sven H. Loosen, Tobias Mueller, Frank Tacke, Christoph Roderburg, Raphael Mohr
Summary: The combination of atezolizumab and bevacizumab has been established as the standard treatment for unresectable hepatocellular carcinoma. However, concerns about its efficacy in non-viral HCC and its safety in patients with advanced cirrhosis remain. This study found that atezolizumab plus bevacizumab showed good efficacy and safety in patients with unresectable HCC, including those with advanced cirrhosis.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti
Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Vera Himmelsbach, Matthias Pinter, Bernhard Scheiner, Marino Venerito, Friedrich Sinner, Carolin Zimpel, Jens U. Marquardt, Joerg Trojan, Oliver Waidmann, Fabian Finkelmeier
Summary: The combination therapy of atezolizumab and bevacizumab has shown high efficacy and manageable toxicity in the treatment of hepatocellular carcinoma, with better prognosis in patients with viral hepatitis.
Article
Oncology
Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yumi Kosaka, Shinsuke Uchikawa, Kenichiro Kodama, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Wataru Okamoto, Shoichi Takahashi, Michio Imamura, Kazuaki Chayama, Hiroshi Aikata
Summary: The study aimed to investigate the early tumor response and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma patients. The results showed that AFP may be useful in assessing early response, and the treatment was safe, including in patients with prior MTA treatments, although adverse events were more frequent in patients with prior treatment.
Article
Oncology
Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Shun Kaneko, Yuki Tanaka, Shun Ishido, Kento Inada, Sakura Kirino, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Ryuichi Okamoto, Namiki Izumi
Summary: The study examined the efficacy and safety of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma based on different treatment lines, showing better clinical outcomes in 1st-line therapy. An early AFP response at 6 weeks could serve as a predictor of disease progression.
INVESTIGATIONAL NEW DRUGS
(2022)
Review
Biochemistry & Molecular Biology
Ji Won Han, Jeong Won Jang
Summary: Atezolizumab in combination with bevacizumab (AB) is the first treatment to show superiority over sorafenib and is now the preferred systemic treatment for HCC patients in stage C. However, a significant number of patients do not achieve survival or significant responses, highlighting the need for predictive biomarkers. This review summarizes current data from experimental and clinical studies, providing valuable information for clinicians and researchers in clinical practice and study design.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Xiaoqiang Gao, Rui Zhao, Huaxing Ma, Shi Zuo
Summary: This study assessed the efficacy and tolerability of atezolizumab plus bevacizumab in the treatment of advanced hepatocellular carcinoma (HCC). The results showed that the combination treatment had an overall response rate of 26%, a complete response rate of 2%, and a partial response rate of 23% in long-term therapy. The median overall survival was 14.7 months and the median progression-free survival was 6.66 months. During the treatment, 83% of patients experienced any grade adverse events and 30% experienced grade 3 and above adverse events. In conclusion, atezolizumab plus bevacizumab demonstrated good efficacy and tolerability in the treatment of advanced HCC.
Article
Oncology
Soichi Takeda, Tadashi Namisaki, Yuki Tsuji, Yuki Fujimoto, Koji Murata, Masahide Enomoto, Yukihisa Fujinaga, Norihisa Nishimura, Koh Kitagawa, Hiroaki Takaya, Kosuke Kaji, Takashi Inoue, Hideto Kawaratani, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji
Summary: This retrospective study evaluated the efficacy and toxicity of atezolizumab plus bevacizumab in patients with advanced-stage hepatocellular carcinoma. The results showed that this treatment regimen is effective and safe in a real-world setting.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study compares the response rates of lenvatinib and atezolizumab plus bevacizumab in the first-line treatment of hepatocellular carcinoma (HCC) patients. The results show that lenvatinib achieves higher response rates in all patient subgroups. Patients who achieve complete response with atezolizumab plus bevacizumab can achieve a better overall survival compared to other treatments.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Soon Kyu Lee, Jung Hyun Kwon, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U. Im Chang, Jin Mo Yang, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Ji Hoon Kim, Ahlim Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Dong Jae Shim, Doyoung Kim, Myungsoo Kim
Summary: This multicenter cohort study compared the clinical outcomes of Atezolizumab-plus-bevacizumab (Ate/Bev) therapy with transarterial chemoembolization plus radiotherapy (TACE + RT) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) and no metastasis. The study found that Ate/Bev treatment provided superior one-year survival compared to TACE + RT treatment, especially in patients with extensive HCC burden. In patients with unilobar intrahepatic HCC, comparable outcomes were observed between the two treatment groups. Ate/Bev treatment should be considered as the primary treatment option for HCC patients with PVTT.
Article
Oncology
Robin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, Ahmed Kaseb, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan Fawcett, Thomas Yau
Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.
Article
Medicine, General & Internal
Hiroyuki Suzuki, Takashi Niizeki, Tomotake Shirono, Yusuke Koteda, Yoshinao Kinjyo, Naohisa Mizukami, Makoto Koda, Satoshi Ota, Masahito Nakano, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Yu Noda, Naoki Kamachi, Akira Kajiwara, Kenji Suda, Jun Akiba, Hirohisa Yano, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Summary: This case report presents a patient with FALD-HCC who achieved good control with low-dose FP therapy. However, the patient ultimately died of extrahepatic metastases.
Article
Radiology, Nuclear Medicine & Medical Imaging
Hideki Iwamoto, Satoshi Itano, Osamu Itano, Masatsugu Ishii, Takashi Niizeki, Tomotake Shirono, Shigeo Shimose, Hiroyuki Suzuki, Akira Kajiwara, Taizo Yamaguchi, Hironori Koga, Takuji Torimura
Summary: The study evaluated the feasibility and safety of the modified System-i for patients with malignant liver tumors using the femoral artery approach. The system was successfully implanted in all patients with a median implantation time of 40 minutes, showing significant results for patients with hepatic artery obstruction or stenosis.
JAPANESE JOURNAL OF RADIOLOGY
(2022)
Article
Multidisciplinary Sciences
Teruko Arinaga-Hino, Tatsuya Ide, Jun Akiba, Hiroyuki Suzuki, Reiichiro Kuwahara, Keisuke Amano, Toshihiro Kawaguchi, Tomoya Sano, Eisuke Inoue, Hironori Koga, Keiichi Mitsuyama, Yasutoshi Koga, Takuji Torimura
Summary: Growth differentiation factor 15 (GDF15) shows potential as a diagnostic and therapeutic marker for autoimmune hepatitis (AIH). It is associated with fibrosis and inflammation in AIH patients and its levels are correlated with disease severity and clinical markers.
SCIENTIFIC REPORTS
(2022)
Article
Gastroenterology & Hepatology
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei-Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiroyuki Suzuki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Summary: This study evaluated the impact of MAFLD on the efficacy of lenvatinib in treating HCC. The results showed that MAFLD was a beneficial factor for survival in HCC patients treated with lenvatinib, especially in those with non-viral HCC.
HEPATOLOGY RESEARCH
(2023)
Article
Oncology
Toshimitsu Tanaka, Hiroyuki Suzuki, Tomoyuki Ushijima, Sachiko Nagasu, Yoshito Akagi, Takumi Kawaguchi, Keisuke Miwa
Summary: This study provides evidence that FOLFIRI plus bevacizumab therapy is a safe and efficient treatment option for patients undergoing hemodialysis with unresectable CRC, and it also suggests that the changes in serum bevacizumab concentration in these patients are similar to those with normal renal function.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Hirona Shigyo, Hiroyuki Suzuki, Toshimitsu Tanaka, Etsuko Moriyama, Yasutaka Shimotsuura, Sachiko Nagasu, Hideki Iwamoto, Yoshito Akagi, Kenta Murotani, Takumi Kawaguchi, Keisuke Miwa
Summary: This study aimed to investigate the safety of Bevacizumab administration early after central venous (CV) port placement. The results showed that the timing of Bevacizumab initiation did not affect the frequency of complications. Therefore, it is safe to administer Bevacizumab early after CV port placement.
Article
Oncology
Hiroyuki Suzuki, Hideki Iwamoto, Takahiro Seki, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Yasuko Imamura, Takashi Niizeki, Masahito Nakano, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Miwa Sakai, Kazutoyo Morita, Masamichi Nakayama, Tomoharu Yoshizumi, Ryoko Kuromatsu, Hirohisa Yano, Yihai Cao, Hironori Koga, Takuji Torimura
Summary: This study aimed to determine the mechanisms underlying antiangiogenic TKI resistance in hepatocellular carcinoma (HCC) patients. The results showed that antiangiogenic TKI treatment increased tumor IGFBP-1 levels and promoted angiogenesis through activating the IGFBP-1-integrin alpha 5 beta 1 pathway. Inhibition of IGFBP-1 and integrin alpha 5 beta 1 could re-sensitize HCC to lenvatinib treatment.
CANCER COMMUNICATIONS
(2023)
Review
Gastroenterology & Hepatology
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Summary: Striking advances in systemic therapy have improved the prognosis of unresectable advanced hepatocellular carcinoma (HCC), resulting in significant changes to the treatment guidelines. However, several issues have emerged, including the lack of established biomarkers to predict treatment response, treatment regimen after primary systemic therapy, and treatment regimen for intermediate-stage HCC, which make the current guidelines ambiguous.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Elina En Li Cho, Chong Zhe Ang, Jingxuan Quek, Clarissa Elysia Fu, Lincoln Kai En Lim, Zane En Qi Heng, Darren Jun Hao Tan, Wen Hui Lim, Jie Ning Yong, Rebecca Zeng, Douglas Chee, Benjamin Nah, Cosmas Rinaldi Adithya Lesmana, Aung Hlaing Bwa, Khin Maung Win, Claire Faulkner, Majd B. Aboona, Mei Chin Lim, Nicholas Syn, Anand V. V. Kulkarni, Hiroyuki Suzuki, Hirokazu Takahashi, Nobuharu Tamaki, Karn Wijarnpreecha, Daniel Q. Q. Huang, Mark Muthiah, Cheng Han Ng, Rohit Loomba
Summary: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. This study determined a high prevalence of NAFLD, non-alcoholic steatohepatitis (NASH), and fibrosis in people with T2DM.
Article
Gastroenterology & Hepatology
Toshimitsu Tanaka, Hironori Koga, Hiroyuki Suzuki, Hideki Iwamoto, Takahiko Sakaue, Atsutaka Masuda, Toru Nakamura, Jun Akiba, Hirohisa Yano, Takuji Torimura, Takumi Kawaguchi
Summary: Therapeutic anti-PD-L1 antibodies promote cell proliferation by stabilizing the PD-L1-AXL complex in liver cancer cells, especially in hepatocellular carcinoma with mesenchymal components.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Hiroyuki Suzuki, Hideki Iwamoto, Toshimitsu Tanaka, Takahiko Sakaue, Yasuko Imamura, Atsutaka Masuda, Toru Nakamura, Hironori Koga, Yujin Hoshida, Takumi Kawaguchi
Summary: This study demonstrates the impact of molecular-targeted agents (MTAs) on the tumor immune microenvironment (TIME) in the treatment of advanced hepatocellular carcinoma (HCC). The results show that cabozantinib activates the innate immune system, while lenvatinib and AZD4547 alter the TIME to a hot immune state by downregulating lipid metabolism-related genes. These findings support the use of combination immunotherapies for HCC treatment.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Masatoshi Tanaka, Tomotake Shirono, Etsuko Moriyama, Yu Noda, Masahito Nakano, Hideya Suga, Ryoko Kuromatsu, Takuji Torimura, Hironori Koga, Takumi Kawaguchi
Summary: This study found that LEN combined with TIT can improve the prognosis of patients with advanced-stage HCC compared to LEN monotherapy. The use of LEN in combination with transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy showed even better results.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Tomotake Shirono, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimose, Akira Kajiwara, Hiroyuki Suzuki, Naoki Kamachi, Yu Noda, Shusuke Okamura, Masahito Nakano, Ryoko Kuromatsu, Kenta Murotani, Hironori Koga, Takuji Torimura
Summary: This study compared the local recurrence-free (LRF) periods of hepatocellular carcinoma nodules with complete necrosis obtained using three different treatment methods: balloon-occluded TACE (B-TACE), conventional TACE (C-TACE), and drug-eluting bead TACE (DEB-TACE). The study found that B-TACE had a significantly longer LRF period compared to C-TACE and DEB-TACE, suggesting B-TACE should be used for radical cure in patients with HCC.
HEPATOLOGY COMMUNICATIONS
(2022)
Article
Oncology
Ryoko Kuromatsu, Tatsuya Ide, Shusuke Okamura, Yu Noda, Naoki Kamachi, Masahito Nakano, Tomotake Shirono, Shigeo Shimose, Hideki Iwamoto, Reiichiro Kuwahara, Teruko Arinaga-Hino, Takashi Niizeki, Yuki Zaizen, Hiroshi Takaki, Miki Shirachi, Hironori Koga, Takuji Torimura
Summary: In patients with hepatitis C virus-related liver disease, the use of direct-acting antivirals (DAAs) after curative hepatocellular carcinoma treatment can effectively suppress its recurrence.